One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The potential of innovative trial design for efficiently evaluating repurposed drugs
James M. S. Wason & Oliver Bandmann
doi : 10.1038/d41573-023-00129-2
Volume 22 Issue 9, September 2023
Alnylam scores big pharma support for angiotensinogen silencer
Asher Mullard
The high, and redundant, cost of failure in cancer drug development
Asher Mullard
Chemoproteomic trailblazer advances covalent candidate into the clinic, pushes allosteric agenda
Asher Mullard
Genomic medicines: the coming waves?
Wen Xie, Baiping Chen & John Wong
Topoisomerase II inhibitor cures trypanosome infections
Sarah Crunkhorn
Peptide vaccine turns up the heat in ALK-positive cancers
Alex Eccleston
Small-molecule discovery through DNA-encoded libraries
Alexander A. Peterson & David R. LiuÂ
The therapeutic potential of targeting regulated non-apoptotic cell death
Kamyar Hadian & Brent R. StockwellÂ
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdis, Mübeccel Akdis, Claus Bachert, Thomas Bieber, Giorgio Walter Canonica, Emma Guttman-Yassky, Martin Metz, Joaquim Mullol, Oscar Palomares, Harald Renz, Sonja Ständer, Torsten Zuberbier & Marcus MaurerÂ
